BFBogdan Iulius Florea

Bogdan Iulius Florea

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Bogdan Iulius Florea has a total of 861 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The development of activity-based mannanase probes

    by Massimo Tedeschi, Vincent A. J. Lit, Nicholas G. S. McGregor, Tessa Gote, Prajeesh Kooloth Valappil, Mark Arentshorst, Bogdan I. Florea, Berend Gagestein, Zachary Armstrong, Jeroen D. C. Codée, et al.

    This paper describes the development of mannobiose, mannotriose, and glucomannose-based probes and their use in reporting on mannanase activities in secretomes from saprophytic bacteria and fungi grown on mannan-containing biomass polysaccharides.


  • Open Access

    Megakaryocytes Internalize and Are Activated by Immune Complexes

    by Florian Puhm, Isabelle Allaeys, Eleonora Petito, Yaqiu Sang, Florian Tupin, Ana dos Santos Pereira Andrade, Etienne Doré, Isabelle Dubuc, Myriam Vaillancourt, Mélanie Dieudé, et al.

    BACKGROUND: Receptors that bind antibodies are essential for protective adaptive immune responses against antibody-opsonized pathogens, yet their engagement by antibody-autoantigen complexes can drive chronic inflammation in autoimmune diseases. Megakaryocytes, the precursor cells of platelets, express such receptors. However, their response to immunoglobulin G antibodies remains unclear. METHODS: We used both systemic lupus erythematosus and COVID-19 as relevant examples of autoimmune and infection-driven contexts in which antibodies are involved to characterize human and mouse megakaryocyte responses. RESULTS: We found that megakaryocytes internalized immune complexes composed of autoantigens or SARS-CoV-2. In both human and mouse megakaryocytes, immune complexes triggered the release of chemokines and procoagulant extracellular vesicles. This process required FcγRIIA engagement, downstream Syk (spleen tyrosine kinase) signaling, and protein translation. A detailed analysis revealed that megakaryocyte-derived extracellular vesicles did not contain organelles and were largely indistinguishable from a subset of small-sized extracellular vesicles released by activated platelets. In FcγRIIA-transgenic mice, we analyzed megakaryocytes in both the bone marrow and lungs in a lupus model, whereas megakaryocytes were examined in the lungs in a COVID-19 model. In all cases, immunoglobulins were detected in close proximity to FcγRIIA-expressing megakaryocytes. Notably, the chemokine CXCL2 was increased in FcγRIIA-expressing mice under disease conditions. Tissue spatial analysis revealed that CXCL2 predominantly localized to megakaryocytes, supporting these cells as a major source. Furthermore, SARS-CoV-2 stimulated megakaryocytes to release CXCL2 only in the presence of IgG from SARS-CoV-2 immune individuals, and this response was strictly dependent on FcγRIIA expression. CONCLUSIONS: These findings suggest that megakaryocytes contribute to adaptive immune responses through FcγRIIA-mediated signaling.


  • Structure-Based Design of Pan-Selective Peptide Epoxyketones for the Three Human Immunoproteasome Active Sites

    by Patrick M. Dekker, Eva M. Huber, Elmer Maurits, Xingzao Wang, Wolfgang Heinemeyer, Bogdan I. Florea, Michael Groll, Herman S. Overkleeft

    The proteasome inhibitors bortezomib, carfilzomib, and ixazomib all act by inhibiting multiple active sites of both constitutive proteasomes and immunoproteasomes. These clinical anticancer drugs are effective, but also display side effects, and evidence is amassing that their toxicity arises from constitutive proteasome inhibition. In this work, we describe the structure-guided discovery of a new class of pan-immunoproteasome-selective inhibitors. We identified the peptide epoxyketone BocPip-Ser (8), which targets all three human immunoproteasome active sites potently and with excellent selectivity over constitutive proteasome active sites (IC50 values for i-subunits ≤ 0.92 μM; IC50 ratio β1c/β1i: 13, β2c/β2i: 14, β5c/β5i: 18; Table 1 and Figure 3). We propose compound 8 (BocPip-Ser), which is of a similar size and general properties as carfilzomib, as a lead compound for the development of improved drugs targeting hematological cancers, and possibly also autoimmune diseases, driven by immunoproteasome but not constitutive proteasome activities.

  • Open Access

    A Highly Specific Monoacylglycerol Lipase PROTAC Probe

    by Axel Hentsch, Mirjam C. W. Huizenga, Yelena Mostinski, Yannick Boer, Tamara Ilioska, Mónica Guberman, Bogdan I. Florea, Joel Rüegger, A. Floor Stevens, Daan van der Vliet, et al.

    The key role of monoacylglycerol lipase (MAGL) in signaling pathways involving endocannabinoids and eicosanoids makes it a promising therapeutic target for numerous diseases, such as (neuro)inflammatory and neuropsychiatric disorders, along with acute tissue damage and cancer. From a mechanistic point of view, MAGL metabolizes the most common endocannabinoid, 2-arachidonylglycerol (2-AG), and additionally influences inflammatory signaling pathways by releasing arachidonic acid (AA). As of now, the therapeutic potential of MAGL has primarily been evaluated through the use of inhibitors and genetic knockout models. Herein, we describe the development of the first reversible MAGL proteolysis targeting chimeras (PROTACs). PROTAC degradation efficiency was dependent on the nature of the linker and E3-ligase system used. Cell permeability was proposed as a main limiting factor for their target engagement and degradation efficacy due to the excessive size and polarity of PROTAC conjugates. Molecular dynamics (MD) simulations revealed a chameleon-like behavior allowing the molecule to hide polar groups by forming intramolecular hydrogen bonds, showing environment-dependent lipophilicity. The best-performing reversible MAGL-PROTAC 4 is permeable, highly efficient with a DC50 < 1.0 nM, and specific in a relevant glioblastoma cell line, which was demonstrated by lipidomic and proteomic analysis. This PROTAC platform enables pharmacological silencing of both MAGLs’ catalytic and potentially elusive structural functions without impacting other proteins. We show that sole modulation of the endocannabinoid system via MAGL degradation using reversible PROTACs potently modulates the endocannabinoid 2-arachidonoyl (2-AG) and therefore holds great therapeutic potential.

  • Open Access

    CellEKT: A Robust Chemical Proteomics Workflow to Profile Cellular Target Engagement of Kinase Inhibitors

    by Joel Rüegger, Berend Gagestein, Antonius P.A. Janssen, Alexandra Valeanu, Alger Lazo Mori, Marielle van der Peet, Michael S. Boutkan, Bogdan I. Florea, Alex A. Henneman, Remo Hochstrasser, et al.


  • Open Access

    Previously Published Phosphatase Probes have Limited Utility Due to their Unspecific Reactivity

    by Franciscus Hendrikus Gerhardus ter Brake, S. A. F. M. van Luttikhuizen, Tom van der Wel, Berend Gagestein, Bogdan Iulius Florea, Mario van der Stelt, Antonius P.A. Janssen

    This study explores the use of activity‐based protein profiling to study protein tyrosine phosphatases. With the discovery of allosteric SHP2 inhibitors, this enzyme family has resurfaced as interesting drug targets. Therefore, we envisioned that previously described direct electrophiles and quinone methide‐based traps targeting phosphatases could be applied in competitive activity‐based protein profiling assays. This study evaluates three direct electrophiles, specifically, a vinyl sulfonate, a vinyl sulfone, and an α‐bromobenzylphosphonate as well as three quinone methide‐based traps as activity‐based probes. For all these moieties it was previously shown that they could selectively engage in assays with purified or overexpressed phosphatases in bacterial lysates. However, this study demonstrates that probes based on these moieties all suffer from unspecific labelling. Direct electrophiles were either unspecific or not activity‐based, while quinone methide‐based traps showed dependence on phosphatase activity but also resulted in unspecific labelling due to diffusion after activation. This phenomenon, termed ′bystander’ labelling, occurred even with catalytically inactive SHP2 mutants. We concluded that alternative strategies or chemistries are needed to apply activity‐based protein profiling in phosphatase research. Moreover, this study shows that quinone methide‐based designs have limited potential in probe and inhibitor development strategies due to their intrinsic reactivity.


  • Open Access

    CellEKT: A robust chemical proteomics workflow to profile cellular target engagement of kinase inhibitors

    by Joel Rüegger, Berend Gagestein, Antonius P. A. Janssen, Alexandra Valeanu, Alger Lazo Mori, Marielle van der Peet, Michael S. Boutkan, Bogdan I. Florea, Alex A. Henneman, Remo Hochstrasser, et al.

    Summary: The human genome encodes 518 protein kinases that are pivotal for drug discovery in various therapeutic areas such as cancer and autoimmune disorders. The majority of kinase inhibitors target the conserved ATP-binding pocket, making it difficult to develop selective inhibitors. To characterize and prioritize kinase-inhibiting drug candidates, efficient methods are desired to determine target engagement across the cellular kinome. In this study, we present CellEKT (Cellular Endogenous Kinase Targeting), an optimized and robust chemical proteomics platform for investigating cellular target engagement of endogenously expressed kinases using the sulfonyl fluoride-based probe XO44 and two new probes ALX005 and ALX011 . The optimized workflow enabled the determination of the kinome interaction landscape of covalent and non-covalent drugs across over 300 kinases, expressed as half maximum inhibitory concentration (IC50), which were validated using distinct platforms like phosphoproteomics and NanoBRET. With CellEKT, target engagement profiles were linked to their substrate space. CellEKT has the ability to decrypt drug actions and to guide the discovery and development of drugs. Graphical


  • Open Access

    Probing the metalloproteome: an 8-mercaptoquinoline motif enriches minichromosome maintenance complex components as significant metalloprotein targets in live cells

    by Sean M. McKenna, Bogdan I. Florea, Daniela M. Zisterer, Sander I. van Kasteren, Joanna F. McGouran

    Affinity-based probes are valuable tools for detecting binding interactions between small molecules and proteins in complex biological environments. Metalloproteins are a class of therapeutically significant biomolecules which bind metal ions as part of key structural or catalytic domains and are compelling targets for study. However, there is currently a limited range of chemical tools suitable for profiling the metalloproteome. Here, we describe the preparation and application of a novel, photoactivatable affinity-based probe for detection of a subset of previously challenging to engage metalloproteins. The probe, bearing an 8-mercaptoquinoline metal chelator, was anticipated to engage several zinc metalloproteins, including the 26S-proteasome subunit Rpn11. Upon translation of the labelling experiment to mammalian cell lysate and live cell experiments, proteomic analysis revealed that several metalloproteins were competitively enriched. The diazirine probe SMK-24 was found to effectively enrich multiple components of the minichromosome maintenance complex, a zinc metalloprotein assembly with helicase activity essential to DNA replication. Cell cycle analysis experiments revealed that HEK293 cells treated with SMK-24 experienced stalling in G0/G1 phase, consistent with inactivation of the DNA helicase complex. This work represents an important contribution to the library of cell-permeable chemical tools for studying a collection of metalloproteins for which no previous probe existed.

  • Open Access

    Immunoproteasomal Inhibition With ONX-0914 Attenuates Atherosclerosis and Reduces White Adipose Tissue Mass and Metabolic Syndrome in Mice

    by Frank H. Schaftenaar, Andrea D. van Dam, Gerjan de Bruin, Marie A.C. Depuydt, Jill de Mol, Jacob Amersfoort, Hidde Douna, Menno Meijer, Mara J. Kröner, Peter J. van Santbrink, et al.

    BACKGROUND: Atherosclerosis is the major underlying pathology of cardiovascular disease and is driven by dyslipidemia and inflammation. Inhibition of the immunoproteasome, a proteasome variant that is predominantly expressed by immune cells and plays an important role in antigen presentation, has been shown to have immunosuppressive effects. METHODS: We assessed the effect of ONX-0914, an inhibitor of the immunoproteasomal catalytic subunits LMP7 (proteasome subunit β5i/large multifunctional peptidase 7) and LMP2 (proteasome subunit β1i/large multifunctional peptidase 2), on atherosclerosis and metabolism in LDLr –/– and APOE*3-Leiden.CETP mice. RESULTS: ONX-0914 treatment significantly reduced atherosclerosis, reduced dendritic cell and macrophage levels and their activation, as well as the levels of antigen-experienced T cells during early plaque formation, and Th1 cells in advanced atherosclerosis in young and aged mice in various immune compartments. Additionally, ONX-0914 treatment led to a strong reduction in white adipose tissue mass and adipocyte progenitors, which coincided with neutrophil and macrophage accumulation in white adipose tissue. ONX-0914 reduced intestinal triglyceride uptake and gastric emptying, likely contributing to the reduction in white adipose tissue mass, as ONX-0914 did not increase energy expenditure or reduce total food intake. Concomitant with the reduction in white adipose tissue mass upon ONX-0914 treatment, we observed improvements in markers of metabolic syndrome, including lowered plasma triglyceride levels, insulin levels, and fasting blood glucose. CONCLUSIONS: We propose that immunoproteasomal inhibition reduces 3 major causes underlying cardiovascular disease, dyslipidemia, metabolic syndrome, and inflammation and is a new target in drug development for atherosclerosis treatment.


  • Open Access

    Human milk oligosaccharide 2’-fucosyllactose protects against high-fat diet-induced obesity by changing intestinal mucus production, composition and degradation linked to changes in gut microbiota and faecal proteome profiles in mice

    by Paola Paone, Dimitris Latousakis, Romano Terrasi, Didier Vertommen, Ching Jian, Valentina Borlandelli, Francesco Suriano, Malin E V Johansson, Anthony Puel, Caroline Bouzin, et al.

    Objective: To decipher the mechanisms by which the major human milk oligosaccharide (HMO), 2’-fucosyllactose (2’FL), can affect body weight and fat mass gain on high-fat diet (HFD) feeding in mice. We wanted to elucidate whether 2’FL metabolic effects are linked with changes in intestinal mucus production and secretion, mucin glycosylation and degradation, as well as with the modulation of the gut microbiota, faecal proteome and endocannabinoid (eCB) system. Results: 2’FL supplementation reduced HFD-induced obesity and glucose intolerance. These effects were accompanied by several changes in the intestinal mucus layer, including mucus production and composition, and gene expression of secreted and transmembrane mucins, glycosyltransferases and genes involved in mucus secretion. In addition, 2’FL increased bacterial glycosyl hydrolases involved in mucin glycan degradation. These changes were linked to a significant increase and predominance of bacterial genera Akkermansia and Bacteroides , different faecal proteome profile (with an upregulation of proteins involved in carbon, amino acids and fat metabolism and a downregulation of proteins involved in protein digestion and absorption) and, finally, to changes in the eCB system. We also investigated faecal proteomes from lean and obese humans and found similar changes observed comparing lean and obese mice. Conclusion: Our results show that the HMO 2’FL influences host metabolism by modulating the mucus layer, gut microbiota and eCB system and propose the mucus layer as a new potential target for the prevention of obesity and related disorders.